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ABSTRACT 
Carbon monoxide (CO) is an endogenous signaling molecule and has therapeutic values. 
However, the application of CO in the development of therapeutic options is hampered by the 
lack of pharmaceutically acceptable delivery methods. Inhalation of CO is not an ideal option for 
wide-spread clinical applications. Existing CO releasing molecules (CORMs) are mostly metal 
complexes, which have toxicity concerns to overcome. Some metal free CORMs have been 
developed. However, they all require light as a trigger to release CO, which limits their 
applications in vivo. Herein, we describe a metal-free CO prodrug approach using an 
intramolecular inverse electron-demanded Diels-Alder reaction. Such prodrugs can release CO 
spontaneously under physiological conditions with tunable release rates with the concomitant 
formation of a fluorescent reporter after CO releases. This intramolecular “click and release” 
strategy represents a milestone in the development of CO based therapeutics. 
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1 INTRODUCTION  
1.1 Background 
Colorless Carbon Monoxide (CO) is toxic at high concentrations due to its ability to bind 
to the hemoglobin in the red blood cells and Cytochrome C oxidase of the mitochondria. CO 
binding of the latter results in the disruption of the oxidative phosphorylation and the respiration 
process.1 Though, inhaling this odorless gas in great amount could be fatal, studies have shown 
that CO is being produced endogenously and low level of CO have therapeutic values. Under 
physiological conditions, the degradation of heme by heme oxygenase produces CO.2-5  This 
endogenously released CO is thought to function as a signaling molecule like that of NO in the 
physiological system.6  In mammals, CO has been reported to play a vital role in neurotransmiss ion 
and regulation of gastrointestinal functions.7,8  Further studies have confirmed that CO functions 
as an anti-inflammatory agent,9-13 can reduce pulmonary hypertension through vascular relaxation, 
and protects the lung from oxidative injuries.14,15 Adding to the list, CO can function as an anti-
tumor agent by causing Warburg effect in the cancer cells - leads to cell dealth.16 CO also can act 
as an anti-bacterial agent by causing the bacteria to produce more ATP that bind and activate 
macrophages for bacterial clearance.17  
Inhaled CO has  shown anti-inflammatory effects; this potentially  means that CO could 
improve tolerance in organ transplantation.12,18  While inhaled CO could possibly be used as a 
therapeutic agent, it is hard to control the CO dose through inhalation.19  Therefore, many CO 
releasing molecules (CO-RMs) have been developed for oral or parental delivery of CO. These 
include metal based CO-RMs, and organic CO-RMs that are activated by light. Some metal-based 
CO can also be activated by light or enzyme. There are pros and cons in each type of CO-RMs that 
limited its applications; this aspect will be discussed in the following section. 
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Figure 1 Carbon Monoxide and Its Therapeutic Values 
Illustraton of the usage of CO as a potential treatment for inflammatory, cancer, and 
bacterial infection.   
 
 
1.2 Carbon Monoxide Releasing Molecules  
Up to this date, the major class of CO-RMs are metal-based with releasing mechanisms 
including hydrolysis/water exchange, enzyme triggering, and photolysis. Below, we summarize 
this area in a brief fashion. 
In 2002, Motterlini and co-workers introduced dimanganese decacarbonyl (Mn2(CO)10) 
and tricarbonyldichloro ruthenium (II) dimer as CO-RMs.20  These CO-RMs were designed to 
release CO in the physiological system to overcome the hurdle of uncontrollable dosage of CO via 
inhalation.  However, these prodrugs were only soluble in DMSO and ethanol, which lead to 
concerns of whether it would be a good fit in physiological system treatment beyond animal 
CO as an anti-tumor agent 
CO as an anti-bacterial agent 
   CO as an anti-inflammatory agent 
Organ transplant 
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models. Thereafter, a water soluble CO prodrug was soon reported as CO-RM-3.21  Despite 
variable release kinetics due to the pH-sensitive nature of  CO release rate,22 CO-RM 3 became 
widely used in CO biological activities studies and yielded many positive therapeutic results.23  
Many other CO-RMs were developed with certain characteristics that facilitate further 
development. One such example is the enzyme trigger CO-released molecules (ET CO-RM). With 
most CO-RMs releasing CO upon exposure to the aqueous environment, the specificity of CO-
RM remains questionable. ET CO-RM was designed to overcome this obstacle, in which it gives 
CO-RM specificity and releases CO at a specific target. Utilizing enzyme abundant in a specific 
physiological site, ET-CO-RMs were able to release CO in a somewhat controllable manner. For 
example, an esterase sensitive CO-RM (Figure 2c), allowed CO release through oxidation after 
cleavage by esterase.24 The ET CO-RMs were designed by taking advantage of the complexation 
of diene and iron - a metal center that could bind to CO, thus could be used as a carrier to deliver 
CO. By trapping the α,β-unsaturated ketone in the enol form though formation of ester, the diene 
is able to form a complex with iron that carried CO. Upon the cleavage of ester bond by an esterase, 
the keto-enol tautomerization occurs. This results in disruption of diene and iron complex, allows 
iron to be release from the scaffold and oxidize to ferric ion and releases CO.25 ET CO-RMs seem 
to be able to overcame the challenges faced by other metal based CO-RMs in term of releasing 
rate, target specificity, and toxicity. Even though Fe is released upon releasing CO, experiments 
have shown that FeCl2 or FeCl3 toxic concentration is higher than that of ET CO-RM.24 Though 
the results suggest this ET CO-RM to be safe, there is no study on the long term effect if this 
prodrug were to be used in therapeutic treatment for an extended period of time. The metal ion 
could possibly accumulate and introduce problem in the long term.  
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At the same time, light mediated CO-releasing molecules (photoCO-RM) were also 
developed.  PhotoCO-RM surpass the hurdle faced by metal-based and enzyme triggerred CO-
RM, in which it is target specific, water soluble, and metal free, and releases CO only upon 
exposure to light.26 One example of metal free photoCO-RM reported was 6-hydroxy-3-oxo-3H-
xanthene-9-carboxylic acid. It was designed such that it would undergo decarbonylation through 
the α-lactone intermediate upon radiated with visible light to release CO.27 This metal-free 
photoCO-RM was able to release CO upon exposure to light at 500 nm with a half-life (t1/2) of 4.5 
h. Nonetheless, the biological test as an anti-inflammatory agent of  this photoCO-RM has not 
been reported up to this date.26,28 Whether it is due to the radiation that masked the effect of CO 
on cell in in vitro studies or other reasons, photoCO-RM has not been reported as a potential 
therapeutic agent. Though even if confirmed to have therapeutic activity, photoCO-RM still will 
face challenges in application beyond in vitro studies where parts of organism that are not exposed 
to light or deeper organs are limited to this prodrug treatment.28  
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Figure 2 Example of Some Existing CO-Releasing Molecules with Various Trigger 
Mechanism. 
a. CO-RM1, dimanganese decacarbonyl (Mn2(CO)10). Photodissociation triggered. b. 
CO-RM3, tricarbonylchloro(glycinato)ruthenium(II) (RuCl(gly)(CO)3). Ligand-exchange 
triggered. c. ET CO-RM, acyloxydiene–iron tricarbonyl complex, release of CO upon 
cleaved by esterase. d. photoCO-RM, 6-hydroxy-3-oxo-3H-xanthene-9-carboxylic acid. 
 
With all the development and their applications in research as tools, such metal-based CO-
RMs face several hurdles that impede their development as therapeutic agents: the lack of 
tunability in CO release rate, the presence of metal, and the lack of structural diversity to allow for 
optimization of solubility, membrane permeability, and stability. Some of the issues can probably 
be overcome with further chemistry efforts; however, the perception of metal toxicity issue might 
be really hard to overcome. Therefore, there is a need for the development of alternative CO-
donors with desirable pharmaceutical develop ability.28 With most CO releasing compounds being 
metal containing,19,29 and the existing limitations of other types of CO-RMs, we would like to 
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introduce metal free CO-prodrugs to address all these concerns including toxicity, and CO release 
rate, among others. 
Our lab has been interested in developing click release system for many applications. One 
of them is the click and release system for the delivery of controllable amount of CO.  We have 
taken advantage of the inverse electron demanded Diels-Alder reactions for the delivery of CO.  
In this type of reaction, the diene is an electron poor specie, while the dienophile is an electron 
rich specie.30  Introducing an electron withdrawing group to the diene lowers its LUMO energy 
while the introduction of an electron donating group to the dienophile brings up its HOMO 
energy.30,31  Thus, bringing HOMO and LUMO closer together allows the reaction between diene 
and dienophile to happen under mild conditions (e.g. physiological conditions).  By changing the 
various substituent groups, the difference between HOMO and LUMO energy gap one should be 
able to tune reaction rate and thus the CO release rate.  This gives an advantage to our click release 
system in which it makes the release rate tunable.  In 2014, our group reported the click and release 
of CO using tetraphenylcyclopentadienone (TPCPD) and strained alkynes (i.e. BCN derivatives).3 2  
Indeed, the bimolecular reaction led to CO release. However, there could be some difficulties for 
a system with two component reactants to work in the physio logical environment. Thus, we would 
like to introduce new molecules for CO release through intramolecular cycloaddition of non-
activated alkyne and dienone compound. With a carbonyl group being electron withdrawing group 
(EWG), we would like to cage a carbonyl group and diene in the form of cyclopentadienone – 
setting up the condition for DAinv reaction. Furthermore, we would like to introduce EWG to the 
dienone ring for two reasons: First, the EWG can stabilize the cyclopentadienone ring and make it 
exist as monomer form for DAinv reaction; Second, the EWG can reduce the LUMO energy of the 
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diene for DAinv to occur to release CO through releasing of the carbonyl group. Herein, the 
synthesis of this types of molecules, the CO prodrugs, is reported. 
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2 RESULTS AND DISCUSSIONS 
By taking advantage of the DAinv, we know that the product of the cycloaddition reaction 
between dienone (diene) and alkyne (dienophile) yields an intermediate that spontaneously 
release CO through chelotropic reaction. Herein, the hurdle to overcome is the cycloaddition of 
the diene and dienophile, because this type of reaction occurs at higher temperature. Fortunately, 
we have come across that the cycloaddition of strained alkyne and diene is possible near 
physiological condition.30 Therefore, we would like to combine such alkyne and diene into one 
molecule to achieve our goal of producing an intramolecular click and release CO prodrugs. 
However, incorporation of a strained alkyne into the same molecule with diene could be 
challenging. Thereafter, we chose to introduce non-strained alkyne into the moiety through ester 
or amide linker, and modified the diene, cyclopentadienone, instead. Through the introduction of 
naphthalene into the cyclopentadienone, we expected lower energy gap between diene and 
dinenophile, allow the cycloaddition reaction to occur to generate intermediate that readily 
release CO. Herein, the synthesis of these CO-prodrugs is shown in Scheme 1. In addition, we 
would like to know if internal alkyne would be able to undergo similar intra-molecular 
cyclization to release CO; thus, an analogue with internal alkyne was synthesized as shown in 
Scheme 2. Solubility has always been an issue with our prodrugs. Due to the hydrophobic nature 
of the phenyl rings contained in our scaffold, they contribute to low water solubility issue of 
these prodrugs. Therefore, we introduced polyethylene glycol (PEG) into the prodrug as shown 
in Scheme 3 to improve water solubility. 
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2.1 Synthesis of CO-Prodrugs 
The synthesis of CO prodrugs is shown in Schemes 1, 2, and 3. Compound 4 was prepared 
through a C-acylation reaction following literature procedures with satisfactory yield (80%).33  
Compounds 6-13 were afforded by reacting compound 5 with intermediate 4 in reflux toluene 
through an esterification or amidation reaction with concomitant decarboxylation.  The reactions 
gave varying yields for different analogues (53 – 98%).  The low yield of 7 and 11 was caused by 
the formation of a side product as shown on the TLC that there was an additional spot with a lower 
Rf. Nonetheless, the optimization of these reactions was not done since we wanted to move 
forward with synthesizing the prodrugs and the reactions gave relatively acceptable yields (enough 
intermediate product for next step).  The final product was acquired through an aldol condensation 
reaction.  Here, Et3N was a strong enough base to deprotonated the alpha proton in 6-13, allowing 
it to act as a nucleophile to attack the carbonyl group in 14 to give intermediates (15).  The 
dehydration of this intermediate upon addition of concentrated H2SO4 produced the desired 
dienone products. Filtration and excessive washing with methanol yielded the pure CO prodrugs 
in 50 – 80% yield. 
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Scheme 1 Synthetic Route for CO Prodrugs.  
i. pyridine, CH2Cl2, ⁰C – r.t., ii. toluene, reflux 110 ⁰C, iii. THF/MeOH, Et3N, iv. acetic 
anhydride, 0 ⁰C, H2SO4 
 
2.2 Synthesis of CO-Prodrugs with Internal Alkyne 
The synthesis of CO prodrug with internal alkyne began with converting the hydroxyl 
group of triethylene glycol monomethyl ether (24) to a good leaving group via tosylation to give 
25 (82%).  Compound 27 was obtained by reacting 25 and 26 in the presence of NaH as a base to 
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deprotonate the proton of the hydroxyl group of 26, making it a good nucleophile for an SN2 
reaction with 25 to afford 27 in 55% yield.  This lower than expected yield was most likely due to 
the solubility of this compound, which affected the ability to extract the product out of the water 
layer during work up process. A strong base, n-BuLi, was used to deprotonate the terminal alkyne 
proton in 27, allowing it to react with 28 to form 29 and 30 in a satisfactory yield (78% and 74% 
respectively).  Reaction of 29 or 30 with 4 gave 31 or 32 with 67% and 61% yield, respectively.  
The low yield of 31 and 32 was caused by the formation of a side product because there was an 
additional spot with a higher Rf on the TLC. This indicated that a specie with lower polarity was 
present in the reaction mixture.  This side product is likely a ketone product that formed by the 
attack of water molecules on the carbonyl ester, which would yield the carboxylic acid side 
product- such compound could undergo decarboxylation to afford the ketone compound.  Ethylene 
glycol is known for its ability to trap water molecules; this must had effected this reaction.  The 
final step of synthesizing these CO analogues is an aldol condensation followed by dehydration as 
mentioned above.  However, in these internal alkyne analogues, BF3•OEt2 was used in dehydration 
because usage of strong acid like H2SO4 resulted in cleavage of the tertiary ester bond in compound 
32.  This is because tertiary ester bond is sensitive to acid and our analogue contained structure 
that would be stable upon cleavage of the ester bond.  Therefore, Lewis acid, BF3-OEt2, was used. 
In the case of 33, the cyclization was so fast that no prodrug was obtained after dehydration step.  
Nevertheless, the reaction product was purified via flash column chromatography to obtain a blue 
fluorescence compound, which was characterized and confirmed by 1H and 13C NMR as the 
cyclized product 33P.  On the other hand, prodrug 34 was stable enough to be obtained.  
12 
 
 
 
Scheme 2 Synthetic Route of CO-Prodrugs with Internal Alkyne.  
i. DCM, Et3N, DMAP, TosCl, 0 ⁰C. ii.NaH, THF, 0 ⁰C to room temperature. iii. n-BuLi, THF, - 
78 oC. iv. Toluene, reflux, v. THF/MeOH, Et3N, room temperature. vi. DCM, 0 ⁰C, BF3OEt2 
*prodrug 33 was not obtained. Only cyclized product of 33 obtained. 
 
2.3 Synthesis of CO-Prodrugs with Improved Water Solubility  
PEG was introduced to the phenyl ring via an SN2 reaction where hydride was used to 
deprotonate phenol proton of 37, allowing it to attack 36 to yield 38 (55% yield). Hydrolysis of 38 
yielded 39 (98%), which underwent condensation reaction with 3 to give 40 in 83% yield. 
Subsequent decarboxylation followed by condensation with 41 gave product 42 in a reasonable 
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yield (84%). Condensation of 14 and 42 followed by dehydration with a strong acid yielded 
product 43 (30%). 
 
Scheme 3 Synthetic Route of CO-Prodrug with Improved Water Solubility. 
i. DCM, Et3N, DMAP, TosCl, 0 ⁰C. ii. NaH, THF, 0 ⁰C to room temperature. iii. LiOH, 
MeOH/H2O (3:1 v/v). iv. DCM, DMAP, 0 ⁰C, EDC. v. chlorobenzene, reflux. vi. Et3N, 
THF/MeOH (3:1 v/v). vii. acetic acid, H2SO4 
 
In concluding of the synthesis of CO-prodrugs, ten CO prodrugs were synthesized, and a 
preliminary test for the release of CO in mixed aqueous solution (DMSO/PBS) was done. It was 
found that all analogues with the exception of analogue 16 were able to undergo intramolecular 
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DAinv to release CO, and the CO release was confirmed by the elucidation of the cyclized products, 
a house hold CO detector and a well-accepted CO-myoglobin assay. The CO release kinetics was 
indirectly studied by monitoring the formation of the cyclized product, which is highly fluorescent. 
The concentration of the prodrug used for studying the reaction kinetics was 50 µM. Fluorescence 
intensity of the cyclized product was measured at different time point to determine the reaction 
rate constant. From this rate constant, the half-life of CO-prodrug was calculated. The results are 
summarized in Table 1. Briefly, with the limited data set, we were able to tune the reaction rate 
over a range of 1000-fold. Compound 22 has a half-life of about 0.2 h and 17 over 10 days.  
In terms of the structure-release rate relationships (SRRR), much of the results agreed with 
what is expected based on structural features. Such consistency further demonstrates the tunability 
of the reaction rates. Generally, the DA is dominated by the entropy factor. For example, our 
prodrugs show that the cycloaddition that lead to 5-membered lactone is more favorable compared 
to that of 6-membered lactone product as shown in the release rate of 16 and 17. This is particular ly 
true for lactam formation also, where forming 5-membered ring lactam product is favorable toward 
cycloaddition reaction.34 Furthermore, our prodrugs with amide linker to conjugate alkyne to the 
cyclopentadiene moiety shows faster release rate compared to that of ester linker. These results 
stay true when gem-methyl and gem-dimethyl alkyne were introduced into the system. The release 
rate increased as we introduced a methyl group to the propargylic- position of alkyne. These results 
suggested that our prodrug is one of a kind that could be tuned to release CO to serve different 
purposes. Such SRRR are discussed in the following sections 
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2.4 Structure-Release Rate Relationship of CO-Prodrugs 
2.4.1 Lactone vs. Lactam Formation on the Release Rate of CO 
After the cycloaddition reaction, the linker portion forms an additional ring structure. In an 
effort to understand the effect of lactam formation vs lactone formation, we compared the reaction 
rates of 18 vs. 21 and 19 vs. 22. It can be seen that the release rate of the cycloaddition reaction 
leading to lactam formation product in 18 and 19 is much faster than the reaction leading to the 
respective lactone, 21 and 22. As the experiments indicated that the half-life of 18, and 19 was 
55.6 + 1.453 h, and 0.549 + 0.0859 h, respectively, while 21 and 22 have half-life of 11.98 + 0.741 
h, and 0.202 + 0.005 h respectively. Such results indicate that the reaction leading to lactam 
formation is much more favorable. This is expected because amide linker is more favorable toward 
the cycloaddition reaction due to entropic factor like conformational constrains. As indicated by 
the experimental results, the rate of CO released is significantly different in the CO analogs with 
the alkyne attached to the prodrug scaffold via an amide bond compared to those attached via an 
ester bond. The faster release of CO in analogs with an amide bond compared to their counterparts 
with an ester bond may be due to the fact that amide bond is more rigid due to the lone pair  
electrons of the nitrogen that allow the nitrogen to form partial double bond, giving raise to the 
rigidity of the molecule. This rigidity fixes the structure of the prodrug (conformationa l 
constraints), and allows alkyne to react with the diene of the prodrug with less of a loss in entropy. 
In the case of those with an ester bond, the lack of rigidity allows rotation around C-O single bond, 
which may have contributed to the slower “click” between the diene and alkyne dienophile. In 
addition, it was reported that the ester bond typically stayed in a transoid geometry due to the 
dipole repulsion. In such a conformation, the cycloaddition would not happen because the diene 
and dienophile do not align in appropriate position.35 
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2.4.2 Ring Sizes Effect on the Release Rate of CO 
In examining the effect of ring size, we want to note that the cycloaddition of 16, which 
should lead to a 6-membered ring lactone product, did not occur, while the cycloaddition of 17, 
which lead to 5-membered lactone ring product, occurred. Though, the release rate of CO was 
slow, half-life of 55.6 + 1.453 h, it is the nature of lactone ring product that would undergoes 
cycloaddition slower than that of lactam. The ring size modification for lactam product is not 
reported in this work, but we have reported the work on CO prodrugs that formed varies lactam 
ring size products.34 Such work indicated that the 5 membered lactam rings were more entropically 
favorable than 6 membered lactam ring.34 The results were in agreement with that of the effect on 
ring size of lactone. 
2.4.3 Dialkyl Effect on the Release Rate of CO 
In examining the effect of additional methyl groups on the linker, we observed that 
introduction of a methyl group to the propargylic carbon increased the rate of cycloaddition. This 
is true for all prodrugs. It was found that the half-life of 20 was more than a week. However,  when 
a methyl group was introduced to the propargylic position, the half-life of 20 was reduced to 
around 12 h, and to about 0.2 h when another methyl group added to the same position in 23. The 
same trend was observed in the ester linker. Prodrug 17 has half-life more than 10 days, while the 
half-life of 18 and 19 is 55 h and 0.5 h, respectively. The drastically increased cycloaddition rate 
with addition of 1 or 2 methyl groups to the propargylic carbon may be due to the entropic effect 
on the prodrugs. The substitution effect on similar intramolecular reactions is well-known in the 
literature.36 Prodrug 20 has potential to form intramolecular hydrogen bonding between amide 
nitrogen proton and the carbonyl of the cyclopentadienone moiety. Such hydrogen bonding was 
hypothesized to hinder the conformation of the molecule from undergo cycloaddition reaction,3 4  
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and thus, resulted in a slow release rate of CO. Nonetheless, upon addition of a methyl group to 
this linker, the release rate increased. This is the result of the gem-dialkyl effect that accelerated 
the cycloaddition rate, where the replacement of hydrogen with methyl group resulted in angle 
depression, forcing the diene and dienophile to be closer.37 The gem-dimethyl effect allowed 
cycloaddition reaction to occur faster, resulting in the tunable rate of our CO prodrugs. We also 
observed this gem-dialkyl effect in the case of an ester linker in prodrugs 17, 18, and 19. Other 
than the gem-dialkyl effect, the introduction of methyl group may have prevented such rotation 
from occurring due to strain that may have added to the compound. Therefore, this allows 
cycloaddition to occur faster as methyl group is added to the linker. These differences in reaction 
rate as methylene group introduced to the prodrug indicated that our prodrugs can be tuned to 
release CO. 
2.4.4 Release Rate of CO in Terminal and Internal Alkyne 
In examining the difference between a terminal and an internal alkyne, we have found that 
the internal alkyne analogs, prodrugs 33 and 34, were able to click and released CO. The half- life 
of 34 was 33.9 + 1.35 h, which is significantly lower than its counterpart 33, the cyclization of 
which was so fast that no prodrug was obtained during synthesis. When comparing the two prodrug 
analogs, the only difference is that 33 contained a 2-methyl groups at the propargylic position, 
while 34 contained only one at the propargylic position. Such results indicate that the different in 
the cycloaddition rate between 33 and 34 is the reflection of the di-alkyl effect as mentioned in the 
earlier discussion. Internal alkyne analog, 34, compared to terminal alkyne, 18, the rate of reaction 
is nearly twice as fast in 34 compared to 18. The direct attachment of the triethylene glycol to the 
alkyne in 34 must have play a role in increasing the reaction rate. It may be because PEG is an 
electron donating group (EDG), and when it attached to a dienophile it will cause the HOMO of 
18 
 
dienophile to be higher. Therefore, the alkyne dienophile in 34 is more favorable toward a DAinv 
reaction compared to that terminal alkyne in 18, resulted in faster cycloaddition rate as shown in 
the experimental data. 
2.4.5 Water Solubility and Release Rate of CO 
In determining the site for modification to increase water solubility, we replaced phenyl 
ring in 22 with methylthio in 23. The results show that the half-life of 22 and 23 were 
insignificantly difference (Table 1), though methylthio is a slightly EDG and should increase the 
LUMO of the diene of our system. Such result suggested that modification in this region does not 
have much effect on our prodrug system. Therefore, we have introduced a PEG into our scaffold 
through the attachment of PEG to the phenyl ring of 18 to afford 43. It was expected that this 
incorporation of PEG into the prodrug would increase the solubility of prodrug; however, studies 
show that it was not the case.  Nonetheless, by incorporating PEG into the scaffold, we found that 
the half-life of this prodrug was 96.8 + 4.45 h. It is two times slower compared to prodrug 18, 
which does not contain the PEG, but all other parts are the same. This must be because of the 
hydrophilicity of PEG that may have been unfavorable to our system, because our system is 
partially powered by the hydrophobic force. Thus, the cycloaddition rate dropped significantly in 
prodrug 43.  Such result opened our prodrugs to another site of modification for tunability to 
release CO.  
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Table 1 CO Release Rates from Prodrugs 
 
 
 
 
 
Prodrugs Rate Constant (h-1) t1/2 (h) 
17 X = O, R1 = Ph, R2 = H, R3 = H, R4 = H, n= 1 - > 10 days 
18 X = O, R1 = Ph, R2 = H, R3 = CH3, R4 = H, n= 1 0.012 + 0.0003 55.6 + 1.45 
19 X = O, R1 = Ph, R2 = CH3, R3 = CH3, R4 = H, n= 1 1.28 + 0.183 0.549 + 0.08 
20 X = NH, R1 = Ph, R2 = H, R3 = H, R4 = H, n= 1 - > 7 days 
21 X = NH, R1 = Ph, R2 = H, R3 = CH3, R4 = H, n= 1 0.058 + 0.003 11.9 + 0.74 
22 X = NH, R1 = Ph, R2 = CH3, R3 = CH3, R4 = H, n= 1 3.424 + 0.097 0.202 + 0.006 
23 X = NH, R1 = Methylthio, R2 = CH3, R3 = CH3,  
      R4 = H, n= 1 
4.626 + 0.281 0.150 + 0.009 
34 X = O, R1 = Ph, R2 = H, R3 = CH3,  
      R4 = triethyleneglycol, n= 1 
0.0204 + 0.0008 33.9 + 1.35 
43 X = O, R1 = p-PEG-Ph, R2 = H, R3 = CH3, R4 = H,      
      n= 1 
0.0071 + 0.0003 96.8 + 4.45 
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2.5 Quantum Yield of CO-Prodrug Cyclized Products 
Absorbance and fluorescence of each cyclized product was measured to determine the 
quantum yield.  By Comparing the collected data (Figure 8, 9, and 10) to the standard, quinine 
sulfate, with a reported quantum yield of 0.546,38 the quantum yields were determined as 0.1484 
+ 0.009, 0.1646 + 0.004, 0.1973 + 0.008, 0.1810 + 0.002, 0.1961 + 0.007,  0.2313 + 0.003, 0.0612 
+ 0.001, 0.1583 + 0.008,  0.1695 + 0.024  for 17P, 18P, 19P, 20P, 21P, 22P, 23P, 34P, and 43P, 
respectively. This quantum yield indicate that the cyclized products of CO-prodrugs have strong 
fluorescence that could be detected upon exposed to UV light. Such data confirmed that our 
prodrugs are readily fluorescence upon release of CO. This gives our prodrugs an advantage in 
real time monitoring of CO release as there is a challenge in the field to detect and track CO release 
from CO-RMs. 
Table 2 Quantum Yields of CO-Prodrugs 
 
Compounds Quantum yield  
at λem = 450 nm, λex = 370 nm 
17P 0.1484 + 0.009 
18P 0.1646 + 0.004 
19P 0.1973 + 0.008 
20P 0.1810 + 0.002 
21P 0.1961 + 0.007 
22P 0.2313 + 0.003 
23P 0.0612 + 0.001 
34P 0.1583 + 0.008 
43P 0.1695 + 0.024 
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2.6 CO-Prodrugs in-vitro Studies 
Among our CO-prodrugs, 19 was selected to test the release of CO in the biological system.  
For such purpose, Hela cells were treated with different concentration of 19 (25 µM and 50 µM) 
for 4 h, and the cells were fixed for fluorescence imaging study under DAPI channel. The results 
are shown in Figure 3. We can clearly see that our CO-prodrug readily undergoes cycloaddit ion 
and releases CO inside Hela cells, as indicated by the blue fluorescence of the cyclized product. It 
was also shown that the fluorescence intensity is dependent on the dose of 19. Such results indicate 
that our CO prodrug could potentially be used as a tool to quantify the amount of the CO being 
delivered to a specific site from such prodrugs.   
 
 
Figure 3 Fluorescence Images of in-vitro Studies of a CO-Prodrug. 
Hela cells were treated with a. 25 µM, b. 50 µM of prodrug 19, incubated for 4 h 
then fixed prior to taken the picture under fluorescence microscope. 
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3 CONCLUSION 
In conclusion, ten metal-free CO prodrugs were synthesized, and their CO release rates 
have been determined. It was observed that there was a trend in the release rate of CO in our 
prodrugs. CO released rate was higher in prodrugs that used an amide linker to link alkyne 
dienophile to the diene scaffold compared to those with an ester linker. Cycloaddition reaction 
rate increase as we introduce a methyl group on the propargylic position. This is true in both 
prodrugs with terminal and internal alkyne. Internal alkynes were also able to undergo click 
reaction to release CO. The release was faster than that of terminal alkyne with PEG attached 
directly to the alkyne dienophile. As per the reaction rate changes with other groups attached in 
place of the PEG, it could possibly be further investigated to open this site for release rate 
tunability of this scaffold. From these kinetics data, we can conclude that we have successfully 
made CO-prodrugs with tunable release rate. Fluorescence quantum yields of the cyclized 
products were determined to be in a range of 0.15 – 0.25. The fluorescence of the product after 
CO release from the prodrug give our organic CO-RM one more advantage over other CO-RMs, 
in which this could be used as an indicator that CO has been released.  
A CO prodrug with potentially improved water solubility was synthesized by introducing 
PEG into the scaffold.  The CO-prodrug shows increased solubility in PBS; however, it was not 
fully soluble without the use of DMSO.  Our future direction in developing organic CO-prodrug 
as therapeutic agents is to focus on producing water soluble CO-prodrugs. Furthermore, we 
would like to perform in vitro and in vivo studies of these prodrugs to examine their anti-
inflammatory effects.   
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4 EXPERIMENTAL 
4.1 General Information 
Starting materials were purchased from Sigma-Aldrich or Oakwood Chemicals, and were 
directly used without further purification. All solvents used in experiments were of purchased 
from Fisher Chemicals. Anhydrous solvents were used for all moisture-sensitive reactions. 
Column chromatography was carried out using flash silica gel (Sorbent 230–400 mesh) and P-2 
Gel (Bio-Gel, particle size range 45- 90 μm). TLC analysis was conducted on silica gel plates 
(Sorbent Silica G UV254). 1H and 13C NMR spectra were recorded at 400 MHz and 100 MHz, 
respectively, on an Avance Bruker 400 NMR spectrometer using deuterated solvent containing 
tetramethylsilane (TMS) or respective solvent as an internal standard. MS were analyzed by the 
Georgia State University Mass Spectrometry Facilities using (ESI)+ or (ESI)-  method. 
4.2 Synthesis of CO-prodrugs 
Synthesis of compound 4 
To the solution of 3 (12 g, 0.08 mol) in DCM (50 mL), pyridine (9.9 g, 0.12 mol) was 
added; then the solution was cooled on an ice bath to 0 ⁰C prior to the dropwise addition of 1 (10 
g, 0.07 mol) or 2 (8.2 g, 0.07 mol). The yellowish solution was stirred at 0 ⁰C for 90 min, and 
then DCM (30 mL) was added to dilute the solution, followed by the addition of 1 M HCl 
solution (30 mL). Extraction was done with DCM (3 , 125 mL). The combined organic layer 
was dried over anhydrous Na2SO4 and concentrated under reduced pressure. Purification was 
done via flash column chromatography (Hex:EtOAc 10:1) followed by recrystallization to afford 
product 4 as white solid (14 g, 80%). R = methylthio, 1H NMR (CDCl3) δ 15.28 (1H, s), 3.94 
(2H, s), 2.26 (3H, s), 1.75 (6H, s). 13C NMR (CDCl3) δ 193.1, 170.7, 160.1, 105.2, 90.4, 35.8, 
26.9, 16.6. 
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Synthesis of compound 6 – 13 
Starting material 4 was dissolved in toluene (3 mL). Then 2 equivalents of 5 was added. 
The solution was heated at reflux for 45 min. Then the solvent was evaporated under reduced 
pressure to afford the crude product.  Purification was done via flash column (Hex:EtOAc 10:1).   
6. But-3-yn-1-yl 3-oxo-4-phenylbutanoate. Colorless oil, yield: 90 mg, 98%. 1H NMR 
(CDCl3): 7.39-7.27 (3H, m), 7.22 (2H, d, J = 6.8 Hz), 4.06 (2H, t, J =2.4 Hz), 3.82 (2H, s), 3.48 
(2H, s), 2.24 (1H, t, J = 2.8 Hz), 1.60 (2H, s), 13C NMR (CDCl3): 204.1, 165.1, 132.8, 129.5, 
129.0, 127.6, 79.1, 71.6, 50.8, 47.5, 29.1. HRMS (ESI)+ calculated for C14H15O3Na [M+Na]+: 
m/z 253.0841, found 253.0829. 
7. Prop-2-yn-1-yl 3-oxo-4-phenylbutanoate.  Colorless oil, yield: 45 mg, 43%. 1H NMR 
(CDCl3): 11.85 (0.2H, s), 7.38-7.21 (6H, m), 4.99 (0.2H, s), 4.73-4.71 (2.6H, m), 3.8 (2.2H, s), 
3.54 (0.5H, s), 3.52 (2.2H, s), 2.53 (1H, t, J = 2.8 Hz), 2.51 (0.25H, t, J = 2.8 Hz), 13C NMR 
(CDCl3): 199.8, 178.2, 171.6, 166.3, 135.3, 133.08, 129.6, 129.3, 128.9, 128.7, 127.5, 127.2, 
89.6, 77.6, 75.5, 75.1, 60.3, 52.7, 51.5, 50.0, 47.8, 41.4, 21.0, 14.2. HRMS (ESI)+ calculated for 
C13H13O3 [M+H]+: m/z 217.0859, found 217.0857. 
8. But-3-yn-2-yl 3-oxo-4-phenylbutanoate. Colorless oil, yield: 82 mg, 94%. 1H NMR 
(CDCl3) δ 7.36 (3H, t, J = 6.0 Hz), 7.24 (2H, d, J = 6.8 Hz), 5.49 (1H, q), 3.85 (2H, s), 3.50 (2H, 
s), 2.50 (1H, d, J = 2 Hz), 1.54 (3H, d, J = 6.8 Hz).  13C NMR (CDCl3) δ 199.9,166.0, 133.1, 
129.6, 128,9, 127.4, 81.5, 73.5, 61.2, 50.0, 48.1, 21.1. HRMS calculated for C14H14O3 [M+Na]+ 
m/z 253.0835, found 253.0836. 
9. 2-Methylbut-3-yn-2-yl 3-oxo-4-phenylbutanoate. Colorless oil, yield: 84 mg, 90%, 
1H NMR (CDCl3) δ 7.36 (2H, t, J = 7.2 Hz), 7.31 (1H, t, J = 6.7 Hz), 7.23 (2H, d, J = 7.4 Hz), 
3.86 (2H, s), 3.44 (2H, s), 2.59 (1H, s), 1.70 (6H, s). 13C NMR (CDCl3) δ 200.3, 165.4, 133.3, 
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129.6, 129.4, 128.9, 127.3, 84.1, 73.1, 72.9, 49.9, 49.0, 28.8. HRMS (ESI)+ calculated for 
C15H16O3Na [M+Na]+: m/z 267.0997, found 267.0984. 
10. 3-Oxo-4-phenyl-N-(prop-2-yn-1-yl)butanamide. Yellow oil, yield: 74 mg, 90%, 1H 
NMR (CDCl3) δ 7.36 (3H, t, J = 7.6 Hz), 7.22 (2H, d, J = 6.8 Hz), 4.06 (2H, d, J = 2.4 Hz), 3.82 
(2H, s), 3.48 (2H, s), 2.24 (1H, t, J = 2.8 Hz). 13C NMR (CDCl3): δ 204.1, 165.1, 132.7, 129.5, 
128.9, 127.5, 79.1, 71.6, 50.8, 47.5, 29.1. HRMS (ESI)+ calculated for C13H14NO2 [M+H]+: m/z 
216.1019, found 216.1012. 
11. N-(But-3-yn-2-yl)-3-oxo-4-phenylbutanamide. Yellow oil, yield: 53 mg, 59%. 1H 
NMR (CDCl3) δ 7.35 (3H, t, J = 7.6 Hz), 7.32 (2H, d, J = 6.8 Hz), 4.79 (1H, m), 3.81 (2H, s), 3.44 
(2H, s), 2.26 (1H, d, J = 2.4 Hz), 1.42 (3H, d, J = 7.2 Hz). 13C NMR (CDCl3) δ 204.2, 164.5, 132.8, 
129.6, 129.0, 128.6, 127.5, 83.8, 70.5, 50.7, 47.8, 36.88, 22.0. HRMS calculated for C14H15NO2Na 
[M+Na]+ m/z 253.1073, found 253.0836. 
12. N-(2-Methylbut-3-yn-2-yl)-3-oxo-4-phenylbutanamide. Yellow oil, yield: 91 mg, 
90%. 1H NMR (CDCl3) δ 7.41 – 7.31 (3H, m), 7.25 – 7.10 (3H, m), 3.82 (2H, s), 3.44 (2H, s), 
2.35 (1H, s), 1.63 (7H, s). 13C NMR (CDCl3) δ 204.7, 164.2, 132.8, 129.6, 129.0, 127.5, 86.8, 
69.2, 50.8, 48.6, 47.4, 29.0. HRMS (ESI)+ calculated for C15H17NO2Na [M+Na]+: m/z 266.1157, 
found 266.1151. 
13. N-(But-3-yn-2-yl)-3-oxo-4-phenylbutanamide. colorless oil, yield: 88 mg, 89%. 1H 
NMR (CDCl3) δ 7.36 – 7.32 (3H, m), 7.21 (2H, d, J = 6.8 Hz), 4.81 – 4.76 (1H, m), 3.81 (2H, s), 
3.44 (2H, s), 2.26 (1H, d, J = 2.4 Hz), 1.42 (3H, d, J = 7.2 Hz). 13C NMR (CDCl3) δ 204.1, 
164.4, 132.8, 129.5, 128.9, 128.5, 127.5, 83.7, 70.5, 50.7, 47.7, 36.8, 21.9. HRMS calculated for 
C14H15NO2 [M+H]+ m/z 230.1176, found 230.1171. 
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Synthesis of compound 16-23 
To the mixture of each compound (6-13) (1.0 mmol) and 15 (1.0 mmol) in THF/MeOH 
(3/1 v/v, 1.6 mL), Et3N (1.5 mmol) was added.  The yellow mixture was stirred at room 
temperature until the solution turned to dark color; then solvent was evaporated under reduced 
vacuum.  2 mL of acetic anhydride was added while the residue was cooled on ice bath. Then the 
reaction was stirred for 30 - 45 min. 2-5 drops of H2SO4 was then added, followed by the 
addition of cold MeOH (10 mL) 10 min later. Filtration under vacuum was done with excessive 
wash with cold MeOH to obtain purple solid product 16-23.   
16. But-3-yn-1-yl 8-oxo-9-phenyl-8H-cyclopenta[a]acenaphthylene-7-carboxylate. 
Dark purple solid, yield:85 mg, 58%. 1H NMR (CDCl3) δ 8.78 (1H, d, J = 7.2 Hz), 8.08-8.03 
(3H, m), 7.93 (1H, d, J = 8.0 Hz), 7.84 – 7.76 (2H, m), 7.63 (1H, d, J = 8 Hz), 7.54 (2H, t, J = 
7.2 Hz), 7.47 (1H, d, J = 8 Hz), 4.55 (2H, t, J = 6.8 Hz), 2.78 (2H, m), 2.10 (1H, t, J = 2.8 Hz).  
13C NMR (CDCl3) 197.0, 170.2, 162.2, 145.2, 131.7, 131.1, 130.6, 130.4, 129.7, 129.2, 129.0, 
128.7, 128.5, 128.5, 127.9, 124.5, 121.4, 109.5, 80.2, 70.2, 62.4, 19.2. HRMS (ESI)+ calculated 
for C26H16O3 [M+H]+: m/z 377.1172, found. HRMS (ESI)+ calculated for C26H16O3Na [M+Na]+: 
m/z 399.0997, found 399.1011. 
17. Prop-2-yn-1-yl 8-oxo-9-phenyl-8H-cyclopenta[a]acenaphthylene-7-carboxylate. 
Purple solid, yield: 60 mg, 80 %. 1H NMR (CDCl3) δ 8.82 (1H, d, J = 7.2 Hz), 8.10 – 8.05 (2H, 
m), 7.94 (1H, d, J = 8.0 Hz), 7.85 – 7.78 (3H, m), 7.64 (1H, t, J = 8.0 Hz), 7.55 (2H, t, J = 7.6 
Hz), 7.48 (1H, d, J = 7.2 Hz), 5.11 (2H, d, J = 8 Hz), 2.62 (1H, t, J = 4 Hz). 13C NMR (DMSO-
d6): 196.5, 170.0, 165.1, 161.0, 150.7, 144.8, 132.4, 131.7, 130.3, 130.0, 129.8, 129.7, 129.7, 
129.6, 129.5, 129.2, 128.8, 128.5, 121.9, 109.0, 79.0, 78.5, 52.3. HRMS (ESI)+ calculated for 
C25H14O3Na [M+Na]+: m/z 385.0841, found 385.0857. 
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18. But-3-yn-2-yl 8-oxo-9-phenyl-8H-cyclopenta[a]acenaphthylene-7-carboxylate. 
Purple solid, yield: 100 mg, 77%. 1H NMR (CDCl3) δ 8.78 (1H, d, J = 7.2 Hz), 8.05 (2H, m), 
7.91 (1H, d, J = 8.4 Hz), 7.81 (2H, m), 7.76 (1H, t, J = 8.0 Hz), 7.61 (1H, t, J = 7.2 Hz), 7.57 
(2H, m), 7.46 (1H, m), 5.78 (1H, m), 2.57 (1H, d, J = 2.0 Hz), 1.74 (3H, d, J = 6.8 Hz). 13C NMR 
(CDCl3) δ 196.8, 170.2, 161.2, 150.9, 145.1, 131.6, 131.1, 130.5,130.4,130.0, 129.7, 129.1, 
129.0, 128.7, 128.6, 128.4, 127.9, 124.5, 121.4, 109.4, 82.3, 73.4, 60.4, 21.5. HRMS (ESI)+ 
calculated for C26H16O3 [M+H]+ 376.1099, found 376.2593. 
19. 2-Methylbut-3-yn-2-yl 8-oxo-9-phenyl-8H-cyclopenta[a]acenaphthylene-7-
carboxylate. Purple solid, yield: 89 mg, 70%. n=1; X = O; R1 = CH3; R2 = CH3, 1H NMR 
(CDCl3) δ 8.91 (1H, d, J = 7.2 Hz), 8.04 (2H, d, J = 7.2 Hz), 7.94 (1H, d, J = 8.4 Hz), 7.83 (2H, 
d, J = 7.6 Hz), 7.77 (1H, t, J = 8.0 Hz), 7.62 (1H, t, J = 8.0 Hz), 7.54 (2H, t, J = 7.2 Hz), 7.46 
(1H, t, J = 6.8 Hz), 2.68 (1H, s), 1.93 (6H, s). 13C NMR (CDCl3) δ 196.1, 170.3, 161.1, 150.8, 
145.1, 131.6, 130.9, 140.7, 130.4, 130.1, 129.6, 129.0, 129.0, 128.7, 128.6, 128.4, 127.8, 124.1, 
121/3. 110.8, 85.0, 72.8, 29.2. HRMS (ESI)+ calculated for C27H18O3Na [M+Na]+: m/z 
413.1154, found 413.1146. 
20. 8-Oxo-9-phenyl-N-(prop-2-yn-1-yl)-8H-cyclopenta[a]acenaphthylene-7-
carboxamide. Purple solid, yield: 80 mg, 70%. 1H NMR (DMSO-d6): 8.85 (1H, d, J = 7.2 Hz), 
8.24 (1H, d, J = 8.4 Hz), 8.13-8.08 (2H, m), 8.02 (1H, d, J = 7.6 Hz), 7.88 (1H, t, J = 7.6 Hz), 
7.79-7.72 (3H, m), 7.60 (2H, t, J = 7.6 Hz), 7.51 (1H, t, J = 7.2 Hz, 1H), 4.16 (2H, d, J = 3.2 Hz), 
3.18 (1H, s). HRMS (ESI)+ calculated for C25H15NO2Na [M+Na]+: m/z 384.1000, found 
384.1017. 
21. N-(But-3-yn-2-yl)-8-oxo-9-phenyl-8H-cyclopenta[a]acenaphthylene-7-
carboxamide. Purple solid, yield: 57 mg, 59%. 1H NMR (CDCl3) δ 9.04 (1H, d, J = 7.2 Hz), 
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8.05 (3H, t, J = 7.6 Hz), 7.94 (1H, d, J = 8.4 Hz), 7.82 (3H, m), 7.63 (1H, t, J = 7.6 Hz), 7.57 
(1H, t, J = 7.2 Hz), 7.49 (2H, d, J = 8.0 Hz), 5.08 (1H, t, J = 8.0 Hz), 2.33 (1H, s), 1.59 (3H, d, J 
= 6.8 Hz). 13C NMR (CDCl3) δ 202.3, 160.7, 152.6, 146.1, 131.7, 130.6, 130.5, 130.4, 130.2, 
129.3, 129.2, 129.1, 128.7, 128.3, 128.1, 121.3, 111.8, 84.3, 70.2, 36.3, 22.2. HRMS (ESI)+ 
calculated for C26H17NO2 [M+H]+: m/z 376.1332, found 376.1329 
22. N-(2-Methylbut-3-yn-2-yl)-8-oxo-9-phenyl-8H-cyclopenta[a]acenaphthylene-7-
carboxamide. Purple solid, yield: 80 mg, 50%. 1H NMR (400 MHz, CDCl3) δ 9.06 (1H, s), 7.99 
(3H, t, J = 8.0 Hz), 7.91 (1H, d, J = 8.0 Hz), 7.77 (3H, t, J = 7.2 Hz), 7.59 (3H, d, J = 7.2 Hz), 
7.48 (1H, d, J = 6.8 Hz), 2.45 (1H, s), 1.81 (6H, s). 13C NMR (100 MHz, CDCl3) δ 202.5, 168.2, 
160.8, 152.7, 146.1, 131.6, 130.4, 129.6, 129.3, 129.0, 128.7, 128.1, 122.9, 121.2, 112.7, 87.2, 
69.2, 46.9, 29.5. HRMS (ESI)+ calculated for C27H19NO2Na [M+Na]+: m/z 412.1313, found 
412.1318. 
23. N-(2-Methylbut-3-yn-2-yl)-9-(methylthio)-8-oxo-8H-
cyclopenta[a]acenaphthylene-7-carboxamide. Dark green solid, yield: 75 mg, 60%. 1H NMR 
(CDCl3) δ 8.96 (1H, d, J = 6.8 Hz), 7.97 (1H, d, J = 8.4 Hz), 7.83 – 7.76 (3H, m), 7.71 (1H, q, J 
= 7.2 Hz), 7.62 (1H, q, J = 7.2 Hz), 2.73 (3H, s), 2.42 (1H, s), 1.77 (6H, s). 13C NMR (CDCl3) δ 
199.4, 168.3, 160.3, 151.3, 145.5, 131.5, 130.6, 130.3, 130.0, 129.8, 129.2, 128.4, 126.9, 121.8, 
121.5, 113.6, 87.2, 69.2, 46.9, 29.5, 14.9. HRMS (ESI)+ calculated for C22H17NO2S [M+H]+: m/z  
360.1053, found: 360.1050. 
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4.3 Synthesis of CO-Prodrugs with Internal Alkyne 
Synthesis of compound 25 - 2-(2-(2-methoxyethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate 
To the solution of 24 (1 g, 6.1 mmol), DMAP (74 mg, 0.61 mmol) and Et3N (740 mg, 7.3 
mmol) in DCM (10 mL) on an ice bath, TosCl (1.7 g, 9.1 mmol) was added portion wise. The 
mixture was stirred at room temperature for 3 hours, then it was directly evaporated under 
reduced pressure.  The crude product was washed and filtered with EtOAc. The filtrate was 
purified by column chromatography (Hex:EtOAc 5:1) to give compound 25. Analytical analysis 
was consistent with previously reported data.39 Oil, 1.78 g, 92%. 1H NMR (CDCl3) δ 7.81 (2H, 
d, J = 8.4 Hz), 7.36 (2H, d, J = 8.0 Hz), 4.17 (2H, t, J = 8.4 Hz), 3.69 (2H, t, J = 4.8 Hz), 3.61 
(6H, t, J = 2.4 Hz), 3.54 (2H, t, J = 2.4 Hz), 3.48 (3H, s), 2.45 (3H, s).  
Synthesis of compound 27 - 2,5,8,11-tetraoxatetradec-13-yne 
To a flask containing NaH (198 mg, 8.2 mmol), THF (6 mL) was added under Argon gas. 
The mixture was cooled to 0 ⁰C for 30 minutes, then 26 (460 mg, 8.2 mmol) was added 
dropwise. The solution was stirred at 0 ⁰C for another 30 minutes, then 25 (1.7 g, 5.5 mmol) in 
THF (5 mL) was added dropwise. The solution then was warmed to room temperature and stirred 
overnight. MeOH was added to the reaction; then it was directly dried under vacuum.  The crude 
product was filtered and washed with diethyl ether. The filtrate was then purified via flash 
column chromatography (Hex:Acetone 10:1) after concentrated under reduced pressure. 
Yellowish oil, yield: 611 mg, 55%. Analytical data were consistent with those previously 
reported.40  1H NMR (CDCl3) δ 4.14 (2H, d, J = 2.4 Hz), 3.65 (10H, m), 3.49 (2H, t, J = 4.4 Hz), 
3.42 (3H, s), 2.40 (1H, t, J = 2.4 Hz). 13C NMR (CDCl3) δ 79.6, 77.5, 76.1, 74.5, 71.9, 70.5, 
70.3, 69.0, 58.9, 58.3.  
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Synthesis of compound 29-30 
To the solution of 27 (600 mg, 3.0 mmol) in THF (5 mL), n-BuLi (1.8 mL, 4.5 mmol) 
was added dropwise at -78 ⁰C. The solution was stirred at -78 ⁰C for an hour; then 28 (6.0 mmol) 
was added dropwise.  After stirring at -78 ⁰C for another hour, the solution was warmed to room 
temperature for 45 minutes. Then, MeOH (5 mL) was dropwise added to the solution over the 
course of 6 min. The reaction mixture then was directly dried under vacuum and used in flash 
column chromatography for purification (DCM:MeOH 40:1).   
29. 15-Methyl-2,5,8,11-tetraoxahexadec-13-yn-15-ol. Clear oil, yield: 608 mg, 78%. 1H 
NMR (CDCl3) δ 4.18 (2H, s), 3.64 (10H, t, J = 6.0 Hz), 3.52 (2H, t, J = 4.4 Hz), 3.35 (3H, s), 
2.69 (3H, s), 1.48 (6H, s).  13C NMR (CDCl3) δ 91.4, 77.7, 77.4, 77.1, 76.8, 71.8, 68.9, 64.9, 
58.9, 58.6, 31.2. HRMS (ESI)+ calculated for C13H24O5 [M+Na]+ 283.1521, found 283.1535.  
30. 2,5,8,11-tetraoxahexadec-13-yn-15-ol. Colorless oil, yield: 546 mg, 74%. 1H NMR 
(CDCl3) δ 4.52 (1H, q), 4.17 (2H, d, J = 1.6 Hz), 3.64 (10H, t, J = 2.4 Hz), 3.60 (3H, t, J = 2.0 
Hz), 3.40 (3H, s), 3.04 (1H, s), 1.39 (3H, d, J = 6.4 Hz). 13C NMR (CDCl3) δ 88.7, 79.4, 76.8, 
71.8, 70.5, 70.4, 70.4, 68.9, 58.9, 58.6, 57.9, 24.2. HRMS (ESI)+ calculated for C12H22O5 
[M+Na]+ 269.1365, Found 269.1357 
Synthesis of compound 31-32 
Solution of 4 (1.6 mmol) and 29(30) (0.8 mmol, 1.0 eq) in toluene (4 mL) was heated at 
reflux for 30 minutes. The solution was then directly dried under reduced pressure, and purified 
via flash column chromatography (Hex:EtOAc 10:1).  
31. 15-methyl-2,5,8,11-tetraoxahexadec-13-yn-15-yl 3-oxo-4-phenylbutanoate. 
Colorless oil, yield: 450 mg, 67%. 1H NMR (CDCl3) δ 7.37 - 7.21 (5H, m), 4.25 (2H, s), 3.84 
(2H, s), 3.64 (12H, t, J = 4.0 Hz), 3.56 (2H, s), 3.42 (3H, s), 1.68 (6H, s), 13C NMR (CDCl3) δ 
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200.4, 165.3, 133.3, 129.6, 129.3, 128.8, 127.3, 86.9, 80.7, 73.4, 71.9, 70.6, 70.4, 69.0, 59.0, 
58.6, 49.9, 49.0, 41.5, 29.1, 28.8  HRMS (ESI)+ calculated for C23H32O7Na [M+Na]+ 443.2046, 
found 443.2045. 
32. 2,5,8,11-tetraoxahexadec-13-yn-15-yl 3-oxo-4-phenylbutanoate. Colorless oil, 
yield: 396 mg, 61%. 1H NMR (CDCl3) δ 7.35 – 7.21 (3H, m), 7.20 (2H, d, J = 6.8 Hz), 5.51 – 
5.49 (1H, m), 4.21 (2H, s), 3.82 (2H, s), 3.63 – 3.54 (12H, m), 3.54 (2H, s), 3.46 (3H, s), 1.48 
(3H, d, J = 6.8 Hz). 13C NMR (CDCl3) δ 200.0, 166.0, 133.1, 129.6, 129.3, 128.9, 128.6, 127.4, 
89.9, 84.2, 81.3, 71.9, 70.6, 70.5, 70.4, 69.1, 61.4, 59.0, 58.5, 50.0, 48.1, 41.4, 21.2. HRMS 
(ESI)+ calculated for C22H30O7Na [M+Na]+ m/z 429.1889, Found 429.1885. 
Synthesis of compound 33-34 
To the mixture of 31 (32) (0.2 mmol) and 14 (0.2 mmol) in THF/MeOH (3/1 v/v, 4 mL), 
Et3N (0.3 mmol) was added. The yellow mixture was stirred at room temperature until the 
solution turned to dark color (3 h), and then dried under reduced vacuum. Two mL of DCM was 
added while the dried residue was cooled on ice bath.  At 0 °C, 5 eq of BF3●OEt2 was added. 
Then the reaction was quenched with cold MeOH. The mixture was diluted with EtOAc (20 
mL), and washed with saturated NaHCO3 solution (20 mL). The organic layer was dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. Flash column chromatography was 
used for purification (Hex:EtOAc 1:1 (100 mL) and EtOAc only).   
34. 2,5,8,11-tetraoxahexadec-13-yn-15-yl 8-oxo-9-phenyl-8H-
cyclopenta[a]acenaphthylene-7-carboxylate. Purple (sticky) solid, yield: 68 mg, 62%. 1H 
NMR (CDCl3) δ 8.81 (1H, d, J = 7.2 Hz), 8.07 (2H, q, J = 8.0 Hz), 7.93 (1H, d, J = 8.0 Hz), 7.82 
(3H, m), 7.63 (1H, d, J = 7.6 Hz), 7.54 (2H, t, J = 7.2 Hz), 7.46 (1H, d, J = 7.6 Hz), 5.84 (1H, d, 
J = 6.4 Hz), 4.29 (1H, s), 3.72 (12H, m), 3.38 (3H, s), 1.72 (3H, d, J = 6.8 Hz).   13C NMR 
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(CDCl3) δ196.9, 170.1, 161.2, 151.0, 145.2, 131.7, 131.1, 130.6, 130.4, 130.2, 129.7, 129.1, 
129.1, 128.7, 128.5, 128.5, 127.7, 124.5, 121.4, 109.5, 85.0, 81.2, 71.9, 70.6, 70.5, 70.4, 69.2, 
60.7, 59.0, 58.7, 21.7. HRMS calculated for C33H35O7 [M+H]+  m/z 553.2221, found 553.2211 
33P (cyclized prodrug) 4-(2,5,8,11-tetraoxadodecyl)-3,3-dimethyl-5-
phenylfluorantheno[7,8-c]furan-1(3H)-one. Yellow Solid, 30 mg. 1H NMR (CDCl3) δ 9.31 
(1H, d, J = 7.2 Hz), 7.97 (1H, d, J = 8.4 Hz), 7.82 (1H, t, J = 8.4 Hz), 7.78 (1H, d, J = 7.6 Hz), 
7.60 (3H, s), 7.51 (2H, d, J = 1.2 Hz), 7.32 (1H, t, J = 7.6 Hz), 6.47 (1H, d, J = 7.2 Hz), 4.41 
(2H, s), 3.63 (6H, t, J = 6.0 Hz), 3.55 (4H, t, J = 8.0 Hz), 3.45 (2H, d, J = 4.4 Hz), 3.37 (3H, s), 
1.93 (6H, s). 13C NMR (CD3OD) δ 169.9, 153.2, 145.9, 139.4, 137.7, 137.2, 135.0, 133.3, 132.6, 
129.7, 129.1, 128.8, 128.7, 128.5, 128.2, 128.0, 127.8, 127.3, 127.2, 123.8, 120.2, 87.5, 71.6, 
69.7, 65.6, 57.6, 26.7 HRMS calculated for C34H37O6 Na+ [M+Na+]+ 561.2248, found 561.2230. 
4.4 Synthesis of CO-prodrug with improved water solubility  
Synthesis of compound 36  
DCM (25 mL) was added to 35 (4 g, 0.014 mol); then DMAP (170 mg, 1.4 mmol) was 
added after the addition of Et3N (1.7 g, 0.016 mol). The solution was cooled to 0 oC, then TosCl 
(3.2 g, 0.016 mol) was added portion wise. The mixture was stirred for an hour on ice bath. Then 
solvent was evaporated. The resulting white solid was washed with EtOAc (50 mL) and filtered 
under vacuum. The filtrate was dried under reduced pressure and purified via flash column 
chromatography (Hex:EtOAc 5:1) for clear liquid product. Yield: 5.9 g, 93 %. Analytical data 
was consistent with those previously reported.41 1H NMR (CDCl3) δ 7.82 (2H, d, J = 8.0 Hz), 
7.36 (2H, d, J = 8.0 Hz), 4.18 (2H, t, J = 4.8 Hz), 3.71 (22H, m), 3.38 (3H, s), 2.46 (3H, s). 
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Synthesis of compound 38 
To the solution of 36 (2 g, 4.5 mmol) in THF (25 mL), NaH (160 mg, 6.8 mmol) was 
added. The mixture was stirred at room temperature for an hour, then 37 (970 mg, 5.8 mmol) in 
THF (15 mL) was added. The mixture was stirred at room temperature for 48 hours, then MeOH 
(4 mL) was added dropwise prior to evaporation of solvent under reduced pressure. EtOAc (30 
mL) was added to the dried solid, then filtration under vacuum was done. The filtrate was dried 
under reduced pressure and purified via flash column chromatography (Hex:EtOAc 1:1 (200 
mL), and then EtOAc only). 1H NMR (CDCl3) δ 7.19 (2H, d, J = 8.8 Hz), 6.88 (2H, d, J = 8.4 
Hz), 4.12 (2H, t, J = 4.8 Hz), 3.85 (27H, m,b), 3.38 (3H, s). 13C NMR (CDCl3) δ 172.3, 157.9, 
130.2, 126.2, 114.7, 71.93, 70.82, 69.71, 67.44, 59.02, 51.97, 40.28. HRMS calculated for 
C22H36O9 [M+Na]+  m/z 467. 2252, found 467.2252. 
Synthesis of compound 39 
MeOH (2 mL) and H2O (0.5 mL) was added to a flask containing 38 (380 mg, 0.85 
mmol) and LiOH (30 mg, 1.3 mmol). The mixture was stirred at room temperature for 24 hours, 
then 2 M HCl solution was added to adjust the solution to pH 5. Then the solution was diluted 
with EtOAc (10 mL), and directly evaporated under reduced pressure. The dried residue was 
purified by flash column chromatography (Hex:EtOAc 1:2) for clear oil product. Yield: 350 mg, 
98%. 1H NMR (CD3OD) δ 7.21 (2H, d, J = 8.0 Hz), 6.91 (2H, d, J = 8.4 Hz), 4.88 (2H, s)), 3.85 
(27H, m, b), 3.35 (3H, s). 13C NMR (CD3OD) δ 157.9, 130.0, 126.9, 114.2, 71.56, 70.36, 70.20, 
70.15, 69.95, 69.47, 67.24, 57.71, 39.70. HRMS (ESI)+ calculated for C21H36O9 [M+H]+ 
432.2348, found 432.2334. 
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Synthesis of compound 41 
The solution of 40 (220 mg, 0.51 mmol), 3 (110 mg, 0.76 mmol), and DMAP (93 mg, 
0.76 mmol) in DCM (10 mL) was cooled on ice bath for an hour. At 0 oC, EDC (118 mg, 0.76 
mmol)) was added portion wise; then the reaction was warmed to room temperature after one 
hour of stirring on an ice bath. The solution was stirred at room temperature for additional 6 
hours. After which, 1 M HCl solution (10 mL) was added to the solution and extraction was done 
with EtOAc (3  25 mL). The combined organic phase was dried over anhydrous Na2SO4, then 
evaporated under reduced pressure to afford the crude product. Flash column chromatography 
(Hex:EtOAc 1:1 (200 mL) and Hex:EtOAc 1:2) was used to purified this crude product to afford 
the pure yellowish liquid product. Yield: 245 mg, 83%. 1H NMR (CD3OD) δ 7.31 (2H, d, J = 8.4 
Hz), 6.88 (2H, d, J = 8.0 Hz), 4.35 (1H, s), 4.11 (25H, complex multiplet protons), 3.38 (3H, s), 
1.72 (5H, s). 13C NMR (CD3OD) δ 195.0, 158.2, 130.6, 130.2, 126.2, 114.8, 114.7, 104.9, 91.18, 
71.92, 70.82, 70.61, 70.56, 70.49, 69.69, 67.43, 59.02, 39.97, 26.81. HRMS calculated for 
C27H40O12 [M+H]+  m/z 579.2417, found 579.2423. 
Synthesis of compound 42 
To the solution of 40 (250 mg, 0.43 mmol) in chlorobenzene (2 mL), but-3-yn-2-ol (41) 
(60 mg, 0.86 mmol) was added. The solution was heated at reflux for 45 minutes; then it was 
cooled to room temperature and directly dried under reduced pressure. The residue was purified 
via flash column chromatography (Hex:EtOAc 1:1 (200 mL), Hex:EtOAc 1:2 (300 mL)). 
Colorless oil, yield: 189 mg, 84%. 1H NMR (CDCl3) δ 7.08 (2H, d, J = 8.4 Hz), 6.85 (2H, d, J = 
8.0 Hz), 5.43 (1H, m), 4.08 (2H, t, J = 4.8), 3.82 (30H, complex multiplet protons), 1.22 (3H, d, 
J = 4.8),). 13C NMR (CDCl3) δ 200.2, 165.9, 157.9, 130.3, 126.4, 114.8, 81.47, 73.56, 70.56, 
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69.56, 67.42, 58.97, 47.92, 21.08. HRMS calculated for C27H40O10 [M+H]+  m/z 525.2694, found 
525.2712. 
Synthesis of compound 43 
To the mixture of 42 (100 mg, 0.19 mmol) and acenaphthylene-1,2-dione (14) (35 mg, 
0.19 mmol) in THF/MeOH (3/1 v/v, 4 mL), Et3N (29 mg, 0.29 mmol) was added.  The yellow 
mixture was stirred at room temperature for 2 hours; then it was concentrated under vacuum.  
Two mL of acetic anhydride was added to the dried residue, then the solution was cooled on an 
ice bath.  After 45 min, 2 - 5 drops of H2SO4 was added. The solution was then diluted with 
EtOAc (10 mL), and added to water (20 mL). Then it was washed with brine (20 mL) and 
saturated NaHCO3 solution (20 mL). The organic phase was dried over anhydrous Na2SO4, and 
evaporated under reduced pressure to afford the crude product, which was purified by silica gel 
column chromatography (Hex:EtOAc 1:1) to afford purple solid product. 38 mg, 30%. 
43.  1H NMR (CDCl3) δ 8.78 (1H, d, J = 7.2 Hz), 8.01 (2H, dd, J = 22.4, 7.7 Hz), 7.89 
(1H, s), 7.75 (3H, dd, J = 18.6, 8.2 Hz), 7.59 (1H, t, J = 7.7 Hz), 7.07 (2H, t, J = 12.5 Hz), 5.75 
(1H, q, J = 6.4 Hz), 4.22 (2H, t, J = 4.7 Hz), 3.91 (1H, d, J = 4.7 Hz), 3.79 – 3.48 (21H, m),  3.37  
(3H, s),  2.56  (1H, s),  1.72  (3H, d,  J  =  6.7  Hz). 13C NMR (CDCl3) δ 197.2, 170.9, 161.3, 
159.7, 148.8, 144.9, 131.6, 131.3, 131.1, 130.6,  130.2,  128.9,  128.6,  128.4,  127.4,  124.4,  
123.2,  121.0,  114.9, 109.0,  82.4,  73.4,  72.0,  70.9,  70.7,  70.6,  70.6,  70.6,  70.5,  69.7,  67.6, 
60.3,  59.0,  21.6.  HRMS  (ESI)+  calculated  for  C39H42O10  [M+H]+  m/z 671.2851, found 
671.2852. 
4.5 General Procedure for Intramolecular DAinv Reactions 
A solution of compound 17-23, 34, and 43 (0.1 mM) in DMSO/PBS (5:1, v/v) was 
incubated at 37 ⁰C for 3 h (prodrugs 19, 22, and 23), one week (18, 21, and 34), or two weeks 
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(17, 20, and 43). After which the featured purple color of compounds 18, 19, 22, 22, 23, and 34 
faded away, and the solution of 17, 20, and 43 was still pale purple and blue. Then the reaction 
was diluted with water (10 mL), and extracted with EtOAc  (25  mL).  The combined organic 
layer was dried over anhydrous Na2SO4, concentrated under vacuum to afford the crude product, 
and purified by silica gel column to afford the cyclized product. 
17P. 5-Phenylfluorantheno[7,8-c]furan-1(3H)-one. Yellow solid, 25 mg, 60%. 1H 
NMR (CDCl3): 9.20 (1H, d, J = 6.8 Hz), 7.97 (1H, d, J = 8.0 Hz), 7.87 (1H, d, J = 8.4 Hz), 7.77 
(1H, t, J = 8.0 Hz), 7.60 (5H, s), 7.41 (1H, t, J = 7.6 Hz), 7.28 (1H, s), 7.19 (1H, d, J = 7.2 Hz), 
5.48 (2H, s). 13C NMR (CDCl3) 171.2, 145.8, 144.2, 139.9, 138.2, 137.9, 135.1, 133.6, 132.4, 
129.6, 128.9, 128.8, 128.7, 128.6, 128.3, 127.6, 127.5, 124.0, 121.6, 120.0, 70.3. HRMS (ESI)+ 
calculated for C24H14O2Na [M+Na]+: m/z 357.0891, found 357.0881. 
18P. 3-Methyl-5-phenylfluorantheno[7,8-c]furan-1(3H)-one. Yellow solid, yield: 40 
mg, 80%. 1H NMR (DMSO-d6) δ 9.09 (1H, d, J = 7.2 Hz), 8.15 (1H, d, J =8.4 Hz), 8.03 (1H, d, 
J = 8.0 Hz), 7.89 (6H, t, J = 7.6 Hz), 7.64 (1H, s), 7.54 (1H, t, J = 7.6 Hz), 7.15 (1H, d, J = 7.2 
Hz), 5.91 (1H, m), 1.71 (1H, d, J = 6.8 Hz). 13C NMR (DMSO-d6) δ 170.4, 151.8, 144.4, 139.8, 
137.3, 137.3, 135.0, 133.5, 132.0, 129.1, 129.7, 129.4, 129.2, 129.1, 128.4, 127.8, 124.2, 122.8, 
120.2, 79.0, 20.8. HRMS (ESI)+ calculated for C25H16O2 [M+H]+ m/z 349.1223, found 349.1832 
19P. 3,3-Dimethyl-5-phenylfluorantheno[7,8-c]furan-1(3H)-one. Yellow solid, yield: 
35 mg, 90%. 1H NMR (CDCl3) δ 9.27 (1H, d, J = 7.0 Hz), 7.99 (1H, d, J = 8.1 Hz), 7.88 (1H, d, 
J = 8.1 Hz), 7.84 – 7.72 (1H, m), 7.68 – 7.55 (5H, m), 7.47 – 7.38 (1H, m), 7.25 – 7.19 (2H, m), 
1.80 (6H, m). 13C NMR (CDCl3) δ 169.9, 154.5, 144.2, 140.1, 138.4, 137.9, 135.1, 133.8, 132.6, 
129.6, 128.8, 128.8, 128.6, 128.3, 127.6, 127.5, 123.9, 120.4, 119.7, 85.8, 27.9. HRMS (ESI)+ 
calculated for C26H18O2Na [M+Na]+: m/z 385.1204, found 385.1213. 
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20P. 5-Phenyl-2,3-dihydro-1H-acenaphtho[1,2-e]isoindol-1-one. Yellow solid, yield: 
30 mg, 62%. 1H NMR (CDCl3): 9.38 (1H, d, J = 6.8 Hz), 7.94 (1H, d, J = 8.0 Hz), 7.85 (1H, d, J 
= 8.0 Hz), 7.79 (1H, t, J = 7.2 Hz), 7.70 – 7.51 (5H, m), 7.39 (1H, t, J = 8.0 Hz), 7.32 (1H, s), 
7.17 (1H, d, J = 7.2 Hz), 6.44 (1H, s), 4.66 (2H, s). HRMS (ESI)+ calculated for C24H15NONa 
[M+Na]+: m/z 356.1051, found 356.1044. 
21P. 3-Methyl-5-phenyl-2,3-dihydro-1H-acenaphtho[1,2-e]isoindol-1-one. Yellow 
solid, yield: 20 mg, 83%. 1H NMR (DMSO-d6) δ 9.29 (1H, d, J = 6.8 Hz), 8.88 (1H, s), 8.05 
(1H, d, J = 8.0 Hz), 7.96 (1H, d, J = 8.0 Hz), 7.82 (1H, t, J = 7.6 Hz), 7.49 (2H, t, J = 7.6 Hz), 
7.10 (1H, d, J = 7.2 Hz), 4.81 (1H, d, J = 6.8 Hz), 1.50 (1H, d, J = 6.4 Hz). 13C NMR (DMSO-
d6) δ 169.9, 149.9, 141.8, 140.4, 136.3, 136.2, 135.7, 134.6, 132.2, 129.8, 129.3, 129.2, 128.9, 
128.9, 128.6, 128.2, 128.1, 127.8, 127.6, 123.5, 123.4, 52.9, 21.0.  HRMS (ESI)+ calculated for 
C25H17NO [M+H]+ 348.1383, Found 348.7222 
22P. 3,3-Dimethyl-5-phenyl-2,3-dihydro-1H-acenaphtho[1,2-e]isoindol-1-one. 
Yellow solid, yield: 35 mg, 95%. 1H NMR (DMSO-d6) δ 9.29 (1H, d, J = 6.9 Hz), 8.88 (1H, s), 
8.05 (1H, d, J = 8.2 Hz), 7.95 (1H, d, J = 8.2 Hz), 7.81 (1H, t, J = 7.6 Hz), 7.62 (4H, m), 7.51 – 
7.38 (2H, m), 7.09 (1H, d, J = 7.2 Hz), 4.81 (1H, d, J = 6.8 Hz), 1.49 (3H, d, J = 6.8 Hz). 13C 
NMR (DMSO-d6) δ 169.8, 149.9, 141.8, 140.4, 136.3, 136.2, 135.7, 134.6, 132.2, 129.8, 129.3, 
129.2, 128.9, 128.8, 128.6, 128.2, 128.1, 127.8, 127.6, 123.5, 123.4, 52.9, 21.0. HRMS (ESI)+ 
calculated for C26H19NO [M+Na]+: m/z 384.1364, found 384.1378. 
23P. 3,3-dimethyl-5-(methylthio)-2,3-dihydro-1H-acenaphtho[1,2-e]isoindol-1-one. 
yellow solid, yield: 30 mg, 96%. 1H NMR (CDCl3) δ 9.33 (1H, d, J = 7.0 Hz), 8.50 (1H, d, J = 
7.1 Hz), 7.94 (2H, dd, J = 16.1, 8.1 Hz,), 7.68-7.77 (2H, m), 7.20 (1H, s), 6.16 (1H, s), 2.75 (3H, 
s), 1.65 (6H, s). 13C NMR (CDCl3) δ 169.6, 153.2, 140.2, 137.4, 135.8, 134.4, 132.4, 129.4, 
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128.6, 128.5, 128.3, 127.6, 127.1, 125.2, 115.2, 59.1, 28.5, 15.3. HRMS (ESI)+ calculated for 
C21H17NOS [M+H]+ 332.1104, found: 332.1102. 
34P. 4-(2,5,8,11-tetraoxadodecyl)-3-methyl-5-phenylfluorantheno[7,8-c]furan-1(3H)-
one. Yellow gummy oil, yield: 25 mg, 80%. 1H NMR (CDCl3) δ 9.24 (1H, d, J = 7.2 Hz), 7.94 
(1H, t, J = 8.0 Hz), 7.81 (1H, d, J = 8.0 Hz), 7.77 (1H, d, J = 7.2 Hz), 7.60 (3H, t, J = 2.8 Hz), 
7.42 (2H, m), 7.32 (1H, t, J = 7.2 Hz), 6.47 (1H, d, J = 7.2 Hz), 6.06 (1H, d, J = 6.4 Hz), 4.56 
(1H, dd, Ja = 11.6; Jb =12 Hz), 3.65 (12H, m), 3.36 (3H, s), 1.79 (3H, d, J = 6.4 Hz).  13C NMR 
(CDCl3) δ 170.7, 150.1, 143.1, 139.2, 137.9, 137.1, 135.4, 133.6, 132.7, 129.5, 129.2, 129.0, 
128.7, 128.6, 128.6, 128.5, 128.4, 127.5, 127.5, 123.9, 121.0, 79.2, 71.9, 70.7, 70.4, 69.8, 67.5, 
59.0, 19.8. HRMS calculated for C33H35O6 [M+3H]3+ 527.2417, found 527.1576  
43P. 5-(4-((2,5,8,11,14,17-hexaoxanonadecan-19-yl)oxy)phenyl)-3-
methylfluorantheno[7,8-c]furan-1(3H)-one. Yellow solid, yield: 15 mg, 63%. 1H NMR 
(CDCl3) δ 9.24 (1H, d, J = 6.8 Hz), 8.00 (1H, d, J = 8.0 Hz), 7.89 (1H, d, J = 8.0 Hz), 7.81 (1H, 
d, J = 8.0 Hz), 7.55 (2H, t, J = 7.6 Hz), 7.44 (1H, d, J = 8.0 Hz), 7.31 (1H, d, J =6.4 Hz), 7.23 
(1H, s), 7.14 (2H, d, J = 8.0 Hz), 5.75 (1H, d, J = 6.4 Hz), 4.40 (2H, t, J = 4.0 Hz), 3.99 (2H, t, J 
= 4.8 Hz), 3.82 (2H, d, J = 4.4 Hz), 3.76 (16H, m), 3.57 (2H, t, J = 4.8 Hz), 3.39 (3H, s), 1.77 
(3H, d, J = 6.4 Hz). 13C NMR (CDCl3) δ 170.62, 159.13, 150.62, 144.03, 138.22, 138.14, 135.23, 
133.76, 132.53, 132.41, 129.99, 129.59, 128.80, 128.56, 128.19, 127.57, 127.52, 124.00, 121. 30, 
119.80, 114.84, 71.93, 70.93, 70.69, 70.67, 70.61, 70.58, 70.52, 69.81, 67.62, 59.04, 53.44, 
29.70, 20.88. HRMS calculated for C38H42O9 [M+H]+ 643.2902, found 643.2910. 
4.6 General Procedure for Reaction Kinetics Studies 
Experiments were performed on SHIMADZU RF-5301PC. Slit width used for excitation 
and emission was 3 nm for all prodrugs except 23, for which the slit width was 5 nm for both 
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excitation and emission. DMSO was added to 0.1 – 0.3 mg of cyclized product of the 
corresponding CO-prodrug to make 50 µM solution. Then the emission and excitation spectra were 
obtained.   
All kinetics were done with 50 µM solution of CO-prodrug in DMSO/PBS (4/1 v/v) in 
triplicate. The λem used was 450 nm, λex was 370 nm. The fluorescence intensity of cyclized product 
of each solution was monitored at different time points. Data points were collected every 2 min 
for the first ten minutes. Then, the duration of data collection varied depending on the rate of 
florescent changes. The fluorescence intensity was plotted against time, and the obtained curve 
was fitted using the Sigmaplot to afford the reaction rate constant. The half-life of the compounds 
was determined per 𝑡1
2⁄
= 0.693 𝑘⁄  where 𝑡1
2⁄
 is the half-life and k is first order reaction rate 
constant.  
.  
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Figure 4 Kinetics Studies of Compound 18, 19, 21. 
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Figure 5 Kinetics Studies of Compound 22, 23, 34. 
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Figure 6 Kinetics Studies of Compound 43. 
 
4.7 General Procedure for Quantum Yield Studies 
DMSO (1%) and MeOH (99%) were added to 1.0 – 1.5 mg of cyclized CO prodrug to 
make 1 mM solution. This 1 mM solution then was diluted to make 4.0, 8.0, 12, 16, and 20 µM 
solutions. The absorbance of each diluted solution was measured at 370 nm on UVvis 
spectrophotometer. Fluorescence of each solution was measured at excitation and emission range 
of 370 nm and 380 – 600 nm respectively. The area under the spectrum curve generated by RF-
5301PC program was plotted against the absorbance at its correspond concentration. The slope of 
the line was compared with the known quantum yield standard, quinine sulfate, for the quantum 
yield of each compound.   
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Figure 7 Quantum Yield Standard Curve 
Integration of fluorescence of Quinine Sulfate plotted against it absorbance at 370 nm excitation 
wavelength. Concentration of Quinine Sulfate were 4.0, 8.0, 12, 16, and 20 mM. A. Slit width used 
for excitation and emission was 3 nm. B. Slit width used for excitation and emission was 5 nm 
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Figure 8 Quantum Yield Graph of Compound 17P, 18P, 19P. 
Integration of fluorescence of each compound cyclized product was plotted against its absorbance 
at 370 nm excitation wavelength. Concentration of each compounds cyclized product were 4.0, 
8.0, 12, 16, and 20 mM in 1% DMSO/MeOH. Slit width used for excitation and emission was 3 
nm 
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Figure 9 Quantum Yield Graph of Compound 20P, 21P, 22P. 
Integration of fluorescence of each compound cyclized product was plotted against its absorbance 
at 370 nm excitation wavelength. Concentration of each compounds cyclized product were 4.0, 
8.0, 12, 16, and 20 mM in 1% DMSO/MeOH. Slit width used for excitation and emission was 3 
nm 
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Figure 10 Quantum Yield Graph of Compound 23P, 34P, 43P. 
Integration of fluorescence of each compound cyclized product was plotted against its absorbance 
at 370 nm excitation wavelength. Concentration of each compounds cyclized product were 4.0, 
8.0, 12, 16, and 20 mM in 1% DMSO/MeOH. Slit width used for excitation and emission was 3 
nm for 34P and 43P. Slit width used for excitation and emission was 5 nm for 23P. 
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APPENDICES 
Appendix A 1H, 13C, and Mass Spectra 
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e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
335.1060
z=1
336.1089
z=1
338.3401
z=1
 
80 
 
 
81 
 
 
 
82 
 
 
 
 
 
VC_I_106_ESIPOS_BWang_08022016 #148-212 RT: 2.13-3.07 AV: 65 NL: 4.30E2
T: FTMS + p ESI Full ms [50.00-1000.00]
375.8 376.0 376.2 376.4 376.6 376.8 377.0 377.2 377.4 377.6 377.8 378.0 378.2 378.4 378.6
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
376.2593
z=1
377.1170
z=?
378.0400
z=?377.2630
z=1
375.8863
z=?
378.0107
z=?
376.1393
z=1
378.1202
z=?
376.2852
z=?
377.3001
z=?
377.6492
z=?
377.1014
z=?
376.8193
z=?
376.4533
z=?
378.2240
z=?
378.5165
z=?
 
 
83 
 
 
84 
 
 
 
85 
 
 
 
 
VC_II_106P_ESIPOS_BWang_08022016 #129-215 RT: 1.86-3.12 AV: 87 NL: 2.13E3
T: FTMS + p ESI Full ms [50.00-1000.00]
347.0 347.5 348.0 348.5 349.0 349.5 350.0 350.5 351.0 351.5 352.0 352.5
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
349.1832
z=1
348.7222
z=?
349.1222
z=1
350.1864
z=1
351.1998
z=1
349.2235
z=? 350.0454
z=?
 
86 
 
 
87 
 
 
  
88 
 
89 
 
90 
 
VC_1_21_ESIPOS_BWANG_022217_170222154119 #154-157 RT: 2.19-2.23 AV: 4 NL: 1.04E7
T: FTMS + p ESI Full ms [100.00-1000.00]
318 320 322 324 326 328 330 332 334 336 338 340 342 344 346 348 350 352
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
334.1217
z=1
335.1248
z=1
338.3403
z=1
341.3035
z=1
 
91 
 
 
92 
 
 
 
93 
 
 
 
VC_II_55_ESIPOS_BWANG_11092016 #117-147 RT: 1.92-2.35 AV: 31 NL: 4.73E6
T: FTMS + p ESI Full ms [50.00-1000.00]
350 355 360 365 370 375 380 385 390 395 400 405 410
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
376.1329
z=1
377.1362
z=1
398.1152
z=1
  
94 
 
 
 
95 
 
 
 
96 
 
VC_II_55P_ESIPOS_BWang_08022016 #99-215 RT: 1.47-3.12 AV: 117 NL: 3.20E4
T: FTMS + p ESI Full ms [50.00-1000.00]
310 320 330 340 350 360 370 380 390 400 410
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
348.1371
z=1
308.9727
z=1
393.2095
z=1352.9891
z=1
386.9890
z=?
368.9841
z=1
315.9730
z=1
329.9888
z=1
385.9277
z=?
325.9163
z=1
310.9695
z=1
335.9450
z=1
370.5738
z=?
354.9848
z=1
394.2129
z=1
409.1835
z=1
306.9423
z=?
344.2278
z=?
365.9556
z=?
 
97 
 
 
 
 
98 
 
  
99 
 
 
 
100 
 
 
101 
 
  
102 
 
 
103 
 
 
m/z
277.0 278.0 279.0 280.0 281.0 282.0 283.0 284.0 285.0 286.0 287.0 288.0 289.0 290.0 291.0 292.0 293.0 294.0 295.0
%
0
100
VC_1_39_ESIPOS_BWANG_062717_2 224 (4.162) AM (Cen,4, 80.00, Ht,5000.0,430.91,0.80); Cm (223:226)
TOF MS ES+ 1.76e3283.1535
281.1036278.1954277.0205 282.7663282.5696
284.1583
284.0491 285.1585284.2573 289.1328
287.1499286.1678
287.6078
288.5167
294.9423292.1723
295.2160
 
104 
 
 
 
 
105 
 
 
106 
 
VaYou_VC_II_62_ESIPOS_BWang_10122016 #136 RT: 2.07 AV: 1 NL: 2.06E8
T: FTMS + p ESI Full ms [50.00-1000.00]
100 200 300 400 500 600 700 800 900 1000
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
269.1357
z=1
C 10 H17 O3 N6
 
107 
 
 
108 
 
 
109 
 
 
 
 
m/z
439.50 440.00 440.50 441.00 441.50 442.00 442.50 443.00 443.50 444.00 444.50 445.00 445.50 446.00 446.50 447.00 447.50 448.00 448.50
%
0
100
VC_11_41_ESIPOS_BWANG_062717_ 279 (5.259) AM (Cen,4, 80.00, Ht,5000.0,430.91,0.80); Cm (279:285)
TOF MS ES+ 2.13e3443.2045
441.1899
439.1992
440.2025439.6431
441.0090440.6844
442.2654441.6424 442.8144
444.2121
443.6017
445.2167
444.9650444.3231
444.7369
445.3084
446.2106445.9487 447.1967446.6110 446.7286 447.9190447.3165 448.3790 448.6902
 
110 
 
 
 
111 
 
 
112 
 
 
 
VaYou_VC_69_ESIPOS_BWang_10122016_2 #170 RT: 2.55 AV: 1 NL: 1.35E8
T: FTMS + p ESI Full ms [50.00-1000.00]
100 200 300 400 500 600 700 800 900 1000
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
429.1885
z=1
461.1785
z=1
 
113 
 
 
  
 
114 
 
 
115 
 
m/z
542.0 544.0 546.0 548.0 550.0 552.0 554.0 556.0 558.0 560.0 562.0 564.0 566.0 568.0 570.0 572.0 574.0 576.0 578.0 580.0 582.0 584.0
%
0
100
VC_11_50_ESIPOS_BWANG_062717_2 234 (4.356) AM (Cen,4, 80.00, Ht,5000.0,430.91,0.80); Cm (231:237)
TOF MS ES+ 3.08e3561.2230
556.2718
549.2267543.2007
541.2435
547.2276
544.2512
555.2631
550.2339
552.4261
554.2119 557.2782 558.2842
560.4408
562.2289
563.2309
566.8883
564.2303 565.2281 577.2084567.0288 575.2126
568.8845
571.1845 572.8799
578.2132
580.9231 583.1955
 
116 
 
 
117 
 
 
118 
 
 
VC_11_71_ESIPOS_BWANG_022217_170222151140 #133-137 RT: 1.87-1.92 AV: 5 NL: 5.36E7
T: FTMS + p ESI Full ms [100.00-1000.00]
525 530 535 540 545 550 555 560 565 570 575 580 585 590 595
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
575.2022
z=1
553.2211
z=1
576.2052
z=1
554.2242
z=1
570.2474
z=1
569.2161
z=1
571.2508
z=1
577.2080
z=1
555.2273
z=1
 
119 
 
 
 
120 
 
 
121 
 
 
VC_II_71P_ESIPOS_BWang_08022016 #98-232 RT: 1.43-3.34 AV: 135 NL: 5.19E4
T: FTMS + p ESI Full ms [50.00-1000.00]
490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
527.1576
z=1
522.2027
z=1
505.1763
z=1
528.1617
z=1
568.1851
z=1
506.1798
z=1 546.2030
z=1
543.1322
z=1
529.1624
z=1
569.1881
z=1
488.1691
z=1
563.2294
z=1
519.1383
z=1
507.1803
z=1
553.1550
z=?
504.5585
z=?
497.5642
z=?
 
122 
 
 
 
123 
 
 
124 
 
 
VaYou_VC_II_77_ESIPOS_BWang_10122016 #183 RT: 2.72 AV: 1 NL: 1.03E8
T: FTMS + p ESI Full ms [50.00-1000.00]
100 200 300 400 500 600 700 800 900 1000
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
467.2252
z=1
445.2439
z=1
 
125 
 
 
 
126 
 
 
127 
 
VC__II_81_ESIPOS_BWANG_11102016 #123-148 RT: 1.95-2.30 AV: 26 NL: 7.04E4
T: FTMS + p ESI Full ms [50.00-1000.00]
429.4 429.6 429.8 430.0 430.2 430.4 430.6 430.8 431.0 431.2 431.4 431.6 431.8 432.0 432.2 432.4 432.6
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
431.2300
z=1
431.1938
z=1
432.2334
z=1
 
128 
 
 
129 
 
 
130 
 
 
VaYou_VC_II_87_ESIPOS_BWang_10122016 #167 RT: 2.50 AV: 1 NL: 5.18E6
T: FTMS + p ESI Full ms [50.00-1000.00]
574 575 576 577 578 579 580 581 582 583 584 585 586 587 588
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
579.2423
z=1
580.2472
z=1
 
131 
 
38. but-3-yn-2-yl 4-(4-((2,5,8,11,14,17-hexaoxanonadecan-19-yl)oxy)phenyl)-3-oxobutanoat
  
132 
 
 
133 
 
 
 
VC_II-101_ESIPOS_BWang_10262016 #123-192 RT: 2.03-3.01 AV: 70 NL: 1.21E5
T: FTMS + p ESI Full ms [50.00-1000.00]
521 522 523 524 525 526 527 528 529 530 531
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
525.2712
z=1
526.2749
z=1
 
134 
 
 
 
135 
 
 
 
136 
 
 
 
VC_II_104_ESIPOS_BWang_08022016 #152-230 RT: 2.15-3.24 AV: 79 NL: 8.14E3
T: FTMS + p ESI Full ms [50.00-1000.00]
669.5 670.0 670.5 671.0 671.5 672.0 672.5 673.0
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
671.2852
z=1
672.2888
z=1
673.2916
z=1
 
137 
 
 
 
 
 
 
138 
 
 
 
 
139 
 
 
 
 
VC_II_104P_ESIPOS_BWang_08022016 #131-216 RT: 1.87-3.10 AV: 86 NL: 9.71E2
T: FTMS + p ESI Full ms [50.00-1000.00]
642.0 642.5 643.0 643.5 644.0 644.5 645.0 645.5 646.0
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
643.2910
z=1
644.2943
z=1
645.2969
z=1
 
